EMA’s Open Trial Data Policy After Five Years: Long Waits, Lengthy Correspondence
By Zachary Brennan -
Published 11 February 2016
The European Medicines Agency’s (EMA) five-year-old policy of allowing some academic researchers and journalists to access what’s considered commercially confidential information in the US has resulted in a lengthy process that can take considerable back and forth correspondence with the agency, according to a new study.
Categories: News, Europe, EMA, Clinical, Drugs, Government affairs, Preclinical, Regulatory intelligence, Regulatory strategy, Research and development
Tags: EMA open trial data, clinical trial data access, freedom of trial information